Neurogene (NGNE)

• Market cap: $274M
• 1 day: -6.51%
• 5 days: -4.49%
• 1 month: -20.13%
• 3 months: -46.71%
• 6 months: -19.25%
• Year to date: -12.4%
• 1 year: 13.72%
• 5 years: -93.25%
• 10 years: -92.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Employees: 107